Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

Amicus Makes Steady Progress Toward Achievement of Milestones

CRANBURY, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the third quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.36 per share ($0.29 per share on a non-GAAP basis) for the three months ended September 30, 2008. As of September 30, 2008, cash, cash equivalents, and marketable securities totaled $136.3 million.

"The third quarter of 2008 was another quarter of strong progress for Amicus as we focused on clinical and regulatory execution on our three lysosomal storage disease programs," said John F. Crowley, President and CEO of Amicus Therapeutics. "In recent months, we have continued the process with regulatory authorities in the United States and Europe in order to define the global development plan for Amigal(TM) in Fabry, and we remain on track to provide an update by the end of the year. In our Gaucher and Pompe disease programs, we continue to focus on advancing our ongoing Phase 2 clinical trials with the goal of reporting data in Gaucher in 2009. Finally, our financial position remains strong based on a healthy balance sheet and on the economics from our strategic alliance with Shire, which funds 50% of development costs for our lead programs in addition to success-based clinical and regulatory milestone payments."

Program Advancements

Fabry Disease:

Amigal (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. Amicus, along with its partner Shire Human Genetic Ther
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today ... fiscal 2015, which ended Feb. 28, increased 13% to ... per share in the current quarter were $0.20, compared ... increased 17% over prior year to $24,142,000, or $0.65 ... for the same period a year ago. ...
(Date:3/26/2015)... March 26, 2015 ReliantHeart, Inc., an ... Transonic, a supplier of precision transit-time flow measurement solutions, ... greatly improve the efficiency of the HeartAssist5® ... patients to experience greater mobility and peace of mind. ... miniature flow board, will draw 1/6th of the power ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will co-present ... Technology, on “ Conducting Postmarket Registries - Rationale and ... and Exhibition on April 25th through April 28th in ... presentation, Ale Gicqueau and Victor Chen will discuss the ... requirements and resources to conduct the registry, as well ...
(Date:3/25/2015)... the most attractive in the emerging European region, mainly ... and increasing government investment in healthcare, according to a ... set to grow at twice the pace of the ... reaching an approximate market value of $43-60 billion by ... Cross provides total healthcare solutions that address the evolving ...
Breaking Biology Technology:Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3
... bacteria, Duke University chemists and engineers have introduced a ... create microdevices such as labs-on-a-chip. , Their inkless microcontact ... nanometer, or billionths of a meter, the Duke team ... Journal of Organic Chemistry. , "This has a ...
... (Nasdaq:,SIAL) is pleased to announce that Patrick M. ... for the Research Biotech business unit, effective,October 1, ... Sigma-Aldrich,s,leadership position through the development of new and ... involved with Sigma-Aldrich,since 2005 as a member of ...
... BIOM ),(TSX: BRA) (the "Company") today announced that, ... in the United States, it intends,to change its name ... shareholder and court approval of a plan of arrangement, ... parent corporation,of a successor corporation of the current Biomira ...
Cached Biology Technology:Using catalysts to stamp nanopatterns without ink 2Using catalysts to stamp nanopatterns without ink 3Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech 2Biomira announces plan to change name to Oncothyreon 2Biomira announces plan to change name to Oncothyreon 3Biomira announces plan to change name to Oncothyreon 4Biomira announces plan to change name to Oncothyreon 5Biomira announces plan to change name to Oncothyreon 6
(Date:3/12/2015)... 2015 The mascots of the Atlantic Coast ... of Wake Forest Baptist Medical Center. They stopped by ... ACC Men,s Basketball Tournament. Young patients enjoyed bonding with ... their autographs. Brenner Children,s Hospital is the ... only children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... BOSTON , March 11, 2015   ... of its platform to scientifically measure and harness ... characteristics to real-time biometrics and objective measurements of ... of music at scale in large populations. It ... scientists, technologists and clinicians perform rigorous studies and ...
(Date:3/10/2015)... OXFORD, Conn. , March 10, 2015 /PRNewswire/ ... NXTDW) ("NXT-ID" or the "Company"), a biometric authentication ... reports the company,s Wocket™ smart wallet has been ... 2015" by Rethink Modern. Rethink Modern ... sharing modern and innovative items for your home and lifestyle that ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... Mutations in a single gene can cause several ... considered different disorders. With support from the National ... exome sequencing a new gene scanning technology that ... mutations. "This is going to change the way ...
... Disease A new compound may offer an effective ... researchers from Brazil. They report their findings in the ... Chemotherapy . Chagas, disease is an infection caused by ... 18 million people and causes up to 50,000 deaths per ...
... , Global plant productivity that once was on the rise ... on the decline because of regional drought according to a ... is a measure of the rate of the photosynthesis process ... and water to sugar, oxygen and eventually plant tissue. Compared ...
Cached Biology News:Gene scan finds link across array of childhood brain disorders 2Gene scan finds link across array of childhood brain disorders 3Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4Drought drives decade-long decline in plant growth 2
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... power supply (Cat. No. Minis 150VS) is ... meet most electrophoresis needs in a personal, ... 150V power supply is capable of running ... designed for individuals to have his/her own ...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: